Sarita Kapila
Stock Analyst at Morgan Stanley
(0.70)
# 4,164
Out of 5,055 analysts
50
Total ratings
42.9%
Success rate
-5.5%
Average return
Main Sectors:
Stocks Rated by Sarita Kapila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Reiterated: Sell | 1,700p → 1,900p | 1,816p | +4.63% | 9 | Aug 25, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €100.00 → €82.00 | €71.82 | +14.17% | 2 | Aug 11, 2026 | |
| RHHBY Roche Holding AG | Upgraded: Buy | $46 → $63 | $55.69 | +13.13% | 3 | Aug 7, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,500p → 15,300p | 12,300p | +24.39% | 12 | Jul 16, 2026 | |
| SNY Sanofi | Reiterated: Hold | $52 → $49 | $39.77 | +23.21% | 4 | Jul 8, 2026 | |
| SWX: ROP Roche Holding AG | Upgraded: Hold | CHF 295.00 | CHF 370.90 | -20.46% | 10 | Apr 24, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Reiterated: Hold | kr 253.10 → kr 257.88 | kr 437.40 | n/a | 2 | May 4, 2023 | |
| BME: GRF Grifols, S.A. | Reiterated: Buy | €14.00 → €16.00 | €9.81 | n/a | 6 | Feb 8, 2023 | |
| GRFS Grifols | Reiterated: Buy | $16 → $18 | $7.24 | n/a | 2 | Feb 8, 2023 |
GSK plc
Aug 25, 2026
Reiterated: Sell
Price Target: 1,700p → 1,900p
Current: 1,816p
Upside: +4.63%
Sanofi
Aug 11, 2026
Reiterated: Hold
Price Target: €100.00 → €82.00
Current: €71.82
Upside: +14.17%
Roche Holding AG
Aug 7, 2026
Upgraded: Buy
Price Target: $46 → $63
Current: $55.69
Upside: +13.13%
AstraZeneca PLC
Jul 16, 2026
Reiterated: Buy
Price Target: 16,500p → 15,300p
Current: 12,300p
Upside: +24.39%
Sanofi
Jul 8, 2026
Reiterated: Hold
Price Target: $52 → $49
Current: $39.77
Upside: +23.21%
Roche Holding AG
Apr 24, 2026
Upgraded: Hold
Price Target: CHF 295.00
Current: CHF 370.90
Upside: -20.46%
Swedish Orphan Biovitrum AB (publ)
May 4, 2023
Reiterated: Hold
Price Target: kr 253.10 → kr 257.88
Current: kr 437.40
Upside: n/a
Grifols, S.A.
Feb 8, 2023
Reiterated: Buy
Price Target: €14.00 → €16.00
Current: €9.81
Upside: n/a
Grifols
Feb 8, 2023
Reiterated: Buy
Price Target: $16 → $18
Current: $7.24
Upside: n/a